AlzeCure shares hit highest since 2022 on $2.2 bln Alzheimer’s drug licensing deal

Investing.com Gold reports: AlzeCure shares hit highest since 2022 on $2.2 bln Alzheimer’s drug licensing deal. Full body text was unavailable at ingest time, so this brief is based on headline context.